Marianne T Sweetser Selected Research

RNAi Therapeutics

1/2021	Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
11/2020	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
9/2020	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
3/2020	Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
3/2020	Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
1/2018	Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marianne T Sweetser Research Topics

Disease

10	Amyloidosis 01/2021 - 01/2019
7	Polyneuropathies (Polyneuropathy) 01/2021 - 01/2018
5	Relapsing-Remitting Multiple Sclerosis 02/2017 - 09/2012
5	Multiple Sclerosis 02/2017 - 09/2012
3	Injection Site Reaction 03/2022 - 11/2020
3	Pain (Aches) 01/2022 - 03/2006
3	Body Weight (Weight, Body) 11/2020 - 01/2018
3	Flushing 01/2020 - 09/2012
3	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2006 - 12/2005
2	Hyperoxaluria (Oxaluria) 03/2022 - 01/2021
2	Primary hyperoxaluria type 1 03/2022 - 01/2021
2	Kidney Calculi (Kidney Stone) 03/2022 - 01/2021
2	Nephrocalcinosis 03/2022 - 01/2021
2	Inborn Genetic Diseases (Disease, Hereditary) 03/2022 - 01/2021
2	Renal Insufficiency (Renal Failure) 03/2022 - 01/2021
2	Cardiomyopathies (Cardiomyopathy) 12/2020 - 01/2020
2	Transthyretin-Related Hereditary Amyloidosis 01/2019 - 01/2018
2	Infections 03/2011 - 12/2005
1	Porphyrias (Porphyria) 11/2020
1	Acute Intermittent Porphyria (Porphyria, Acute) 11/2020
1	Diabetic Neuropathies (Diabetic Neuropathy) 09/2020
1	Orthostatic Intolerance 03/2020
1	Disease Progression 01/2019
1	Abdominal Pain (Pain, Abdominal) 09/2012
1	Diarrhea 09/2012
1	Nausea 09/2012
1	Rheumatoid Arthritis 03/2011
1	Pneumonia (Pneumonitis) 03/2011
1	Neoplasms (Cancer) 12/2005

Drug/Important Bio-Agent (IBA)

10	Prealbumin (Transthyretin)IBA 01/2021 - 01/2019
8	patisiranIBA 01/2021 - 01/2018
5	Dimethyl FumarateIBA 02/2017 - 09/2012
3	Pharmaceutical PreparationsIBA 01/2021 - 06/2014
3	Alefacept (Amevive)FDA Link 07/2006 - 12/2005
2	lumasiranIBA 03/2022 - 01/2021
2	OxalatesIBA 03/2022 - 01/2021
2	Acute Hepatic PorphyriaIBA 01/2022 - 11/2020
2	Hemin (Panhematin)FDA Link 01/2022 - 11/2020
2	PorphobilinogenIBA 01/2022 - 11/2020
2	givosiranIBA 01/2022 - 11/2020
2	revusiranIBA 12/2020 - 01/2020
2	Transaminases (Aminotransferases)IBA 11/2020 - 09/2012
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2020
2	Glatiramer Acetate (Copaxone)FDA Link 10/2013 - 09/2012
1	Aminolevulinic Acid (Levulan)FDA Link 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2021
1	CreatinineIBA 11/2020
1	Valine (L-Valine)FDA Link 01/2020
1	Methionine (L-Methionine)FDA Link 01/2020
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 06/2014
1	Natalizumab (Tysabri)FDA Link 06/2014
1	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 06/2014
1	AntigensIBA 06/2014
1	GoldIBA 10/2013
1	InterferonsIBA 09/2012
1	Etanercept (Enbrel)FDA Link 03/2011
1	Methotrexate (Mexate)FDA LinkGeneric 03/2011
1	Adalimumab (Humira)FDA Link 03/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2011
1	Rituximab (Mabthera)FDA Link 03/2011
1	Tumor Necrosis Factor InhibitorsIBA 03/2011
1	Biological ProductsIBA 07/2006
1	AntibodiesIBA 12/2005

Therapy/Procedure

6	RNAi Therapeutics 01/2021 - 01/2018
3	Therapeutics 01/2019 - 12/2005
1	Intravenous Administration 11/2020
1	Phototherapy (Light Therapy) 07/2006